Johnson & Johnson Price to Book Ratio 2012-2026 | JNJ
Historical price to book ratio values for Johnson & Johnson (JNJ) over the last 10 years. The current price to book ratio for Johnson & Johnson as of September 14, 2026 is 7.55.
| Johnson & Johnson Price/Book Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | Book Value per Share | Price to Book Ratio |
| 2026-09-15 | 267.20 | 7.57 | |
| 2026-06-30 | 252.72 | $35.28 | 7.16 |
| 2026-03-31 | 241.82 | $33.73 | 7.17 |
| 2025-12-31 | 203.65 | $33.86 | 6.01 |
| 2025-09-30 | 181.32 | $32.95 | 5.50 |
| 2025-06-30 | 148.28 | $32.61 | 4.55 |
| 2025-03-31 | 159.62 | $32.47 | 4.92 |
| 2024-12-31 | 138.09 | $29.70 | 4.65 |
| 2024-09-30 | 153.51 | $29.14 | 5.27 |
| 2024-06-30 | 137.41 | $29.72 | 4.62 |
| 2024-03-31 | 147.53 | $29.09 | 5.07 |
| 2023-12-31 | 145.07 | $28.57 | 5.08 |
| 2023-09-30 | 143.01 | $29.59 | 4.83 |
| 2023-06-30 | 150.89 | $29.41 | 5.13 |
| 2023-03-31 | 140.24 | $27.27 | 5.14 |
| 2022-12-31 | 158.68 | $29.39 | 5.40 |
| 2022-09-30 | 145.80 | $28.51 | 5.11 |
| 2022-06-30 | 157.38 | $29.04 | 5.42 |
| 2022-03-31 | 156.13 | $28.41 | 5.49 |
| 2021-12-31 | 149.74 | $28.16 | 5.32 |
| 2021-09-30 | 140.44 | $26.69 | 5.26 |
| 2021-06-30 | 142.41 | $26.44 | 5.39 |
| 2021-03-31 | 141.19 | $25.01 | 5.65 |
| 2020-12-31 | 134.37 | $24.04 | 5.59 |
| 2020-09-30 | 126.23 | $24.49 | 5.15 |
| 2020-06-30 | 118.45 | $23.92 | 4.95 |
| 2020-03-31 | 109.69 | $23.28 | 4.71 |
| 2019-12-31 | 121.25 | $22.59 | 5.37 |
| 2019-09-30 | 106.80 | $22.13 | 4.83 |
| 2019-06-30 | 114.12 | $23.01 | 4.96 |
| 2019-03-31 | 113.76 | $22.20 | 5.12 |
| 2018-12-31 | 104.32 | $22.44 | 4.65 |
| 2018-09-30 | 110.99 | $24.09 | 4.61 |
| 2018-06-30 | 96.82 | $23.45 | 4.13 |
| 2018-03-31 | 101.51 | $23.58 | 4.30 |
| 2017-12-31 | 109.97 | $22.43 | 4.90 |
| 2017-09-30 | 101.70 | $27.55 | 3.69 |
| 2017-06-30 | 102.83 | $26.78 | 3.84 |
| 2017-03-31 | 96.18 | $26.10 | 3.68 |
| 2016-12-31 | 88.38 | $26.02 | 3.40 |
| 2016-09-30 | 90.00 | $26.73 | 3.37 |
| 2016-06-30 | 91.80 | $26.47 | 3.47 |
| 2016-03-31 | 81.31 | $26.40 | 3.08 |
| 2015-12-31 | 76.63 | $25.82 | 2.97 |
| 2015-09-30 | 69.13 | $25.86 | 2.67 |
| 2015-06-30 | 71.63 | $25.69 | 2.79 |
| 2015-03-31 | 73.40 | $24.45 | 3.00 |
| 2014-12-31 | 75.77 | $25.06 | 3.02 |
| 2014-09-30 | 76.73 | $27.31 | 2.81 |
| 2014-06-30 | 74.81 | $27.65 | 2.71 |
| 2014-03-31 | 69.75 | $27.08 | 2.58 |
| 2013-12-31 | 64.57 | $26.25 | 2.46 |
| 2013-09-30 | 60.69 | $24.75 | 2.45 |
| 2013-06-30 | 59.66 | $24.75 | 2.41 |
| 2013-03-31 | 56.23 | $23.85 | 2.36 |
| 2012-12-31 | 47.96 | $23.33 | 2.06 |
| 2012-09-30 | 46.74 | $23.08 | 2.02 |
| 2012-06-30 | 45.41 | $21.97 | 2.07 |
| 2012-03-31 | 43.91 | $22.35 | 1.96 |
| 2011-12-31 | 43.27 | $20.95 | 2.07 |
| 2011-09-30 | 41.64 | $22.52 | 1.85 |
| 2011-06-30 | 43.10 | $22.67 | 1.90 |
| 2011-03-31 | 38.06 | $21.86 | 1.74 |
| 2010-12-31 | 39.38 | $20.66 | 1.91 |
| 2010-09-30 | 39.11 | $20.85 | 1.88 |
| 2010-06-30 | 36.93 | $19.19 | 1.92 |
| 2010-03-31 | 40.40 | $19.19 | 2.11 |
| 2009-12-31 | 39.61 | $18.37 | 2.16 |
| 2009-09-30 | 37.15 | $18.27 | 2.03 |
| 2009-06-30 | 34.38 | $16.79 | 2.05 |
| 2009-03-31 | 31.56 | $15.87 | 1.99 |
| 2008-12-31 | 35.60 | $15.35 | 2.32 |
| 2008-09-30 | 40.88 | $16.45 | 2.49 |
| 2008-06-30 | 37.72 | $16.61 | 2.27 |
| 2008-03-31 | 37.77 | $16.19 | 2.33 |
| 2007-12-31 | 38.57 | $15.25 | 2.53 |
| 2007-09-30 | 37.76 | $15.17 | 2.49 |
| 2007-06-30 | 35.18 | $14.90 | 2.36 |
| 2007-03-31 | 34.18 | $14.14 | 2.42 |
| 2006-12-31 | 37.23 | $13.59 | 2.74 |
| 2006-09-30 | 36.42 | $13.97 | 2.61 |
| 2006-06-30 | 33.41 | $13.89 | 2.41 |
| 2006-03-31 | 32.81 | $13.83 | 2.37 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $641.804B | $94.193B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $1071.528B | 36.15 |
| AbbVie (ABBV) | United States | $462.493B | 24.08 |
| Merck (MRK) | United States | $357.370B | 45.12 |
| Roche Holding AG (RHHBY) | Switzerland | $349.105B | 0.00 |
| Novartis AG (NVS) | Switzerland | $265.214B | 16.01 |
| Novo Nordisk (NVO) | Denmark | $194.004B | 10.81 |
| Pfizer (PFE) | United States | $157.995B | 9.09 |
| Sanofi (SNY) | France | $105.050B | 8.84 |
| Bayer (BAYRY) | Germany | $56.081B | 9.98 |
| Innoviva (INVA) | United States | $1.510B | 5.16 |